One More Plea for Avastin in Breast Cancer
Posted on 08. Aug, 2011 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — As Genentech awaits word from the FDA on whether bevacizumab (Avastin) will lose its breast cancer indication, the company is urging the agency to consider a “middle ground” approach that would continue the drug’s approval in metastatic disease.
Read Full Article…
One More Plea for Avastin in Breast Cancer
Posted on 08. Aug, 2011 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — As Genentech awaits word from the FDA on whether bevacizumab (Avastin) will lose its breast cancer indication, the company is urging the agency to consider a “middle ground” approach that would continue the drug’s approval in metastatic disease.
Read Full Article…
Washington Week: ACA Ruling, FDA Panel Move Top News
Posted on 02. Jul, 2011 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — The first federal appeals court to rule on the healthcare reform law upheld the constitutionality of the individual mandate, and an FDA panel recommended that bevacizumab (Avastin) no longer be used to treat breast cancer.
Read Full Article…
Medicare to Keep Paying for Avastin
Posted on 30. Jun, 2011 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — Medicare will continue to pay for bevacizumab (Avastin) when it’s used to treat metastatic breast cancer, even if the FDA decides to remove that indication from the drug, a spokesman for the Centers for Medicare and Medicaid Services (CMS) said.
Read Full Article…
FDA Panel Votes to Yank Avastin’s Breast Cancer Indication
Posted on 29. Jun, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — SILVER SPRING, Md. — An FDA advisory committee has voted unanimously, 6-0, that Genentech’s bevacizumab (Avastin) should no longer be approved to treat metastatic HER2-negative breast cancer.
Read Full Article…
FDA Unswayed by Pleas to Retain Breast Ca Indication
Posted on 28. Jun, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — SILVER SPRING, Md. — FDA officials held firm in their view that bevacizumab (Avastin) should not be used to treat breast cancer during a heated first day of a two-day hearing, at which breast cancer patients pleaded with the agency to keep the drug available.
Read Full Article…
FDA to Look Again at Drug’s Breast Ca Indication
Posted on 27. Jun, 2011 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — The FDA’s Center for Drug Evaluation and Research is holding a two-day hearing this week at the request of bevacizumab (Avastin) maker Genentech to reconsider its decision to rescind the drug’s breast cancer indication.
Read Full Article…
FDA Sees No New Safety Signals for Silicone Breast Implants
Posted on 22. Jun, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — The FDA’s preliminary review of postmarketing safety studies on silicone breast implants, released Wednesday, found no evidence that the products increase the risk of breast cancer, reproductive abnormalities, or other problems.
Read Full Article…
Brits Say No to Avastin for Breast Cancer
Posted on 25. Feb, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — Women with metastatic breast cancer did not benefit from treatment with bevacizumab (Avastin) compared with other available therapies, a British regulatory agency concluded in a decision not to recommend the indication.
Read Full Article…
Firm Asks for Full FDA Hearing on Bevacizumab
Posted on 18. Jan, 2011 by Dr. Ellis in News and Updates
(MedPage Today) — As it had promised, Genentech is mounting a full-court press to keep the breast cancer indication for bevacizumab, which the FDA proposed in December to withdraw.
Read Full Article…
